Profile data is unavailable for this security.
About the company
Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.
- Revenue in USD (TTM)4.70bn
- Net income in USD486.90m
- LocationCatalent Inc14 Schoolhouse RdSOMERSET 08873-1213United StatesUSA
- Phone+1 (732) 537-6200
- Fax+1 (732) 537-6480
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|CTLT:NYQ since |
|Erytech Pharma SA-Cell Therapy Manufacturing Facility,Princeton,NJ||Deal completed||25 Apr 2022||25 Apr 2022Deal completed||18.71%||44.50m|
|The Vaccine Manufacturing & Innovation Centre||Deal completed||18 Feb 2022||18 Feb 2022Deal completed||9.86%||--|
|Bettera Holdings LLC||Announced||30 Aug 2021||30 Aug 2021Announced||-17.11%||1.00bn|